The specificity of mutant-specific KRASG12C inhibitors for mutant KRAS in cancer cells without inhibiting wild-type KRAS in normal cells has helped to define the role of oncogenic KRAS signalling in modulating anti-tumour immune responses. Here, KRAS is linked to neoplasm.